PYGL and cancer: It was reported that expression of TP53 markedly enhanced the susceptibility to cisplatin and cisplatin-induced cell death in variable cancers [55–57], and we discovered that low TP53 expression in HNSCC was closely associated with higher IC50 of cisplatin while TP53 was proved to have negative correlation with PYGL in expression level.